← SageRanks

Lynch on the GRANOLAS

This ranking weighs PEG ×4, Revenue growth ×3, ROE ×2, Analyst upside ×1, Buy % ×1, and nothing else, across the 11 companies we track on the GRANOLAS. 3 of them clear Lynch’s hard limits right now.

Ranked highest by Lynch on this market right now, which is not the same list as the one that clears the limits above:

  1. ASML (ASML) · Technology · PEG 1.47 · Revenue growth 21.3% · ROE 54% · Analyst upside 28.4% · Buy % 89%
  2. AstraZeneca (AZN) · Healthcare · PEG 1.28 · Revenue growth 6.4% · ROE 22% · Analyst upside 33.1% · Buy % 90%
  3. SAP (SAP) · Technology · PEG 1.64 · Revenue growth 9.4% · ROE 18% · Analyst upside 20.1% · Buy % 81%
  4. Roche (RHHBY) · Healthcare · PEG 1.49 · Revenue growth -1.2% · ROE 38% · Analyst upside 13.6% · Buy % 50%
  5. L'Oréal (LRLCY) · Consumer Defensive · PEG 2.31 · Revenue growth 5.8% · ROE 19% · Analyst upside 18.7% · Buy % 75%

From data as of 2026-09-11 01:00:55 UTC. Rebuilt every hour; the table above is live.

All 11 companies on the GRANOLAS, ranked by Lynch, as text
  1. ASML (ASML) · PEG 1.47 · Revenue growth 21.3% · ROE 54% · Analyst upside 28.4% · Buy % 89%
  2. AstraZeneca (AZN) · PEG 1.28 · Revenue growth 6.4% · ROE 22% · Analyst upside 33.1% · Buy % 90%
  3. SAP (SAP) · PEG 1.64 · Revenue growth 9.4% · ROE 18% · Analyst upside 20.1% · Buy % 81%
  4. Roche (RHHBY) · PEG 1.49 · Revenue growth -1.2% · ROE 38% · Analyst upside 13.6% · Buy % 50%
  5. L'Oréal (LRLCY) · PEG 2.31 · Revenue growth 5.8% · ROE 19% · Analyst upside 18.7% · Buy % 75%
  6. Novo Nordisk (NVO) · PEG 3.36 · Revenue growth 2.1% · ROE 60% · Analyst upside 7.2% · Buy % 29%
  7. Sanofi (SNY) · PEG 29.56 · Revenue growth 14.6% · ROE 6% · Analyst upside 25.7% · Buy % 50%
  8. LVMH (LVMUY) · PEG 1.58 · Revenue growth -2.9% · ROE 17% · Analyst upside 30.4% · Buy % 33%
  9. Nestlé (NSRGY) · PEG 2.14 · Revenue growth -2.5% · ROE 26% · Analyst upside 16.2% · Buy % 40%
  10. GSK (GSK) · PEG 95.97 · Revenue growth 5.3% · ROE 33% · Analyst upside 21.7% · Buy % 14%
  11. Novartis (NVS) · PEG 3.41 · Revenue growth 0.8% · ROE 30% · Analyst upside 14.8% · Buy % 42%